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1. INTRODUCTION aeid substitution in the TTR molecule [t3]. WC have 
now determined the eBNA sequence of TTR in a pa- 
tient with advanced SSA and show chat the sequence is 
identical with previously published normalTTRgenomic 
DNA and cDNA sequences. 
Amyloid is a pathological fibrillar substance, depos- 
ited between cells. The exact spatial structure of the 
amyloid fibril is not known although a ,&pleaced sheer 
conformation is believed to be of importance [ 11, Sever- 
al different small proteins can aggregate to amyloid 
fibrils, There are 2 groups of amyloid syndromes in 
which the main fibril protein is transthyretin (TTR, 
previously prcalbumin) or fragments thereof, These 
comprise most forms of familial amyloidosis [2-51 and 
the age-related senile systemic amyloidosis (SSA) [6,7]. 
In the TTR-derived familial amyloidoses, point muta- 
tions in the TTR gene, leading to single amino acid sub- 
stitutions have invariably been found. Several different 
substitutions pread over the TTR molecule have been 
connected to amyloid syndromes [3-5,8-lo]. Wow the 
amino acid substitutions are connected to the fibril for- 
mation has so far not been explained. 
The familial amyleidoses are comparably rare. SSA, 
on the other hand, is a very common disorder affecting 
about 25% of individuals over 90 years old. However, 
few of these have more than very mild disease [11,12]. 
In spite of this frequency, it has been claimed that §§A 
might also be a hereditary disorder linked to an amino 
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2. MATERIALS AND METHODS 
Tlrc studies wcrc performed on a 9l-year-old man (patient 4) who 
died from cardiac insufficiency. Amyioidosis was not suspected clini- 
cally but itI ~ntopsy, an cniargcd heart (490 g) with the appearnnce of 
amyloid infiltration was found, Myocordiai and liver tissue were 
frozen at - 70°C. Pieces of various tissues were fixed in formalin and 
embedded in paraffin. Congo red stained sections from the myocar- 
dium revealed massive amyloid infiltration, and small amyloid depos- 
its were found in several other organs, Immunohistochemicai ex- 
arninntion revealed a reaction of the amyioid with a previously char- 
acterized antiserum to ATTR [ 121. This antiserum does not react with 
arnyioid of AA or AL-type. The clinical appearance and the histo- 
pathological and immunohistochemicai findings were typical of SSA 
IL?]. 
2.2. Protein srudies 
Only about 2 g of myocardium was available for amyloid fibrii ex- 
traction, This was performed as described 171. The fibrils in SSA have 
previously been shown to contain fragments of TTR and full length 
TTR (TTR-like protein) [7,14,15]. Since the fragments do not react 
with antiserum to TTR [14], the TTR-like protein of patient 4 was 
partially purified by covalent chromatography and gel filtration as de- 
scribed [7,15]. Sodium dodecyl sulphate polyacrylamidc gel electro- 
phoresis was performed as described [16]. For Western blot analysis 
[17] proteins were transferred to Immobilon PVDF transfer mem- 
brane (Miilipore, Bedford, MA). With the latter, rabbit antiserum to 
TTR (DAKO, Copenhagen) was usedi diluted 1:20, The protein 
band, corresponding to TTR, was also cut-out and applied directly to 
a 477A automatic sequence analyzer (Applied Biosystems) with an 
on-line 120A PTW amino acid analyzer for N-terminal analysis. 
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Fig. I. Principle for IIX TTR EDNA rynthcsis, nmplificrrtien and xcqucnslng. E, ,QoRt site; B, &&+I site, 
Taral cellrrlnr RNA wasextracted fram approximately 2 g of frozen 
liver tissue using the LiCVurca method [l8]. Poly(A)” RNA was cn. 
richcd through chromatography on oligo(clT) cellulose (Pharmncin, 
Uppsala, Sweden) and used for oligo(dT)-primed first srrand cDNA 
synthesis using an Amcrshnm cDNA synthesis kit (Amcrshnm, Buck- 
inghamshirc. UK), IO-50 ng of cDNA was used for polymerasc chain 
reactions using a SCIWC primer corresponding to the 5’.untranslated 
sequence of the human TTR cDNA scqucncc [I91 immediately up. 
stream of the translation initiation site (5’-AATCGAGAATTCAGT- 
CCACTCATTCTTGCCAGG) and an antisense primer complcmcn- 
tary to the 3’-untranslated sequence immediately downstream of the 
translation stop codon (5’.ATTCGAGGATCCCACTGGAGGAGA. 
AGTCCCTCA), The primers included an &oRI she and a BurnHI 
site respectively in their 5’“ends to facilitatcsubctoning of the amplifi. 
cation product. Thcrmostablc DNA polymcrase was purchased from 
Pcrkin Elmer Cctus (Norwalk, CT) and used as recommended by the 
manufacturer. The following PCR cycle temperature profiles were 
used: 94’C, 1 min; 54”C, 10 min; 72”C, 30 min. for 2cyctes, followed 
by 94”C, 1 min; 54”C, 2 min; 72OC, 4 min, for 28 cycles. Analysis of 
10% of the amplification reaction product on a I .5% agarosc/TBE 
gel showed only one DNA band of the expected size (507 bp). The 
reaction products from each of 2 independent cDNA syntheses and 
subsequent amplification materials were purified by isotachophoresis 
1201, cleaved by EcoRI and Bu/nHl and subcloncd in Ml3mp18/19 
vectors. The complete sequences of 10 clones from the first cxperi- 
mcnt and additional 5 clones from the 2nd experiment were detcr- 
mined by dideoxynucleotidc sequencing methodology [21] using Sc- 
quenasc reagents (USB Biochemicals, Cleveland, OH). An outline of 
the strate8y to reveal the TTR cDN.4 sequence is shown in Fig. 1) 
3. RESULTS 
3.1. Transthyretin ature L$ the umyloid ,fifibrils 
In order to prove the TTR-origin of the amyloid in 
patient 4, analysis of the constituent fibrit protein was 
done. SDS-PAGE of the partially purified amyloid fi- 
bril protein revealed 3 closely situated bands of which 
the predominant had a mobility similar to monomeric 
TTR (Mr = 14 000). Western blot analysisof the material 
in this band revealed astrong reaction with antiserum to 
TTR (Fig. 2). Furthermore, N-terminal amino acid anal- 
ysis of the material gave the sequence NH& )-Pro-Thr- 
Gly-Thr-Gly-Giu-Ser-, identical with positions 2-8 of 
TTK [19]. 
3.2. cDNA sequence of transthyretin 
PCR using primers specific for the untranslated se- 
quences flanking the TTR mRNA resulted in the ampli- 
fication of a single DNA fragment (Fig. 3) of expected 
size. This fragment was purified from 2 independent ex- 
periments, subcloned and sequenced. Fifteen randomly 
picked TTR-positive Ml3 clones, 10 from the 1st and 5 
from the 2nd experiment had a DNA sequence identical 
to that of normal TTR genomic [22] and complemen- 
tary [19] DNA (Fig. 4). 
4. DISCUSSION 
An important question concerning the pathogenesis 
of SSA and other TTR-derived amyloidoses i whether 
or not TTR with normal primary structure can give rise 
to amyloid fibrils in vivo. In the most studied group of 
TTR-amyloidosis, the familial amyloidoses, mutant 
TTR has always been found, but the fibxils usually have 
A! B 
IQ. 3, hnnly%ix or rlrc PCR rcacrian using nywoxc act clccrrophurrrix 
fOlluwcd hyethirlium bromide nnining xhewxawxlally P single DNA 
nnrplificntian predurr Of the wpccted sire (587 hp). HudW3X174 
restric~iun rmgmcwr nrr shown ws molecular weiyht markcra (MW). 
The sizer Of 2 al rhc frnymcms nrc gkcn in bnrc pniro, 
Fill. 1, (A) SDS-PAGE 0r parrinlly purified nmylaid fihril prutcin. 
The rrrong bnnd with sllghlly slower nrobiliry than lynosynic rcncred 
stranyly with :wri-TTR nntibotlisx in Wcstcrn blot anrrlysis (13). Mo- 
Icculnr wcipht wwirrtls (hnre) arc (from abavc): bavinc swum 
albumin, 6G kBa; ovnlhumin, 4S kDn; soyhcnn trypsin inhihiw, 
20.4 kB0; lysoxymc, 14.4 kDil; and apradnin, 6 kDa, 
been shown to contain normal TTR as well 123,241. In
a recent study of the amyloid from one patient with 
typical SSA, we resolved the primary structure of the 
whole ATTR molecule and we were unable to find any 
sequentially abnormal TTR-component [151. However, 
most of the amyloid was composed of TTR-fragments 
of varying length and a TTR-variant with an amino acid 
substitution in the lacking part of the molecule could 
theoretically have been present. To exclude this possi- 
bility, we found it important o determine the structure 
of TTR cDNA from another patient with proven SSA, 
For this study we chose material from a 91-year-old 
man (patient 4) with typical §§A. The TTR nature of the 
amyloid was shown by immunohistochemistry, Western 
blot analysis of the partially purified amyloid fibril pro- 
tein, and N-terminal amino acid sequence analysis. All 
the cDNA sequences derived from this second patient 
were normal. Due to the absence of a polymorphic se- 
quence within the TTR coding sequence that distin- 
guishes the 2 TTR alleles in this patient, we cannot com- 
pletely exclude the possibility that what we have am- 
plified represents he rranscription product of only one 
of the TTR ailelcs. However, if a mutant TTR allele was 
prcscnt, this must have been expressed at low level since 
in 2 independent experiments, all analyzed clones had 
tllc normal nucleotidc sequence. In addition, the cDNA 
could be diluted 100.fold without loss of the TTR- 
amplification product, In combination with the pre- 
vious reports on normal amino acid sequences of TTR 
purified frotn SSA patients [6,7,15] the present result 
strongly suggests that TTR with normal primary struc- 
ture is the sole constituent of amyloid fibrils in SSA, 
which is the most common form of TTR-derived 
amyloidosis. This is an important finding since it shows 
that mechanisms other than variations in the primary 
structure of TTR are important for the fibril formation 
in SSA and probably also in other TTR-derived amyloid 
forms. 
Recently, several investigations have reported a iso- 
leucine-for-valine substitution in patients with amyloid 
disorder, resembling SSA in that it mainly affects the 
heart [13,25-273. However, several facts indicate that 
these patients, rather than having SSA, represent anew 
form of familial amyloidosis with cardiomyopathy: all 
the patients tudied were black, and the amyloid disease 
seems to have occurred at a much ydunger age than in 
§§A, which is a disease of the very old [12]. Therefore, 
in typical SSA, no variant TTR seems to be involved in 
the pathogenesis of the disease. 
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